| References |
1. Brezak MC, Valette A, Quaranta M, Contour-Galcera MO, Jullien D, Lavergne O, Frongia C, Bigg D, Kasprzyk PG, Prevost GP, Ducommun B. IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. Int J Cancer. 2009 Mar 15;124(6):1449-56. doi: 10.1002/ijc.24080. PubMed PMID: 19065668. 2. Frongia C, Lorenzo C, Gianni F, Prevost GP, Ducommun B, Lobjois V. 3D imaging of the response to CDC25 inhibition in multicellular spheroids. Cancer Biol Ther. 2009 Dec;8(23):2230-36. Epub 2009 Dec 3. PubMed PMID: 19823027. 3. Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706. PubMed PMID: 26515730; PubMed Central PMCID: PMC4741984. 4. Sarkis M, Miteva MA, Dasso Lang MC, Jaouen M, Sari MA, Galcéra MO, Ethève-Quelquejeu M, Garbay C, Bertho G, Braud E. Insights into the interaction of high potency inhibitor IRC-083864 with phosphatase CDC25. Proteins. 2017 Apr;85(4):593-601. doi: 10.1002/prot.25236. Epub 2017 Jan 18. PubMed PMID: 28056492. |
